TITLE

Sanctions agreed over teenager's gene-therapy death

AUTHOR(S)
Check, Erika
PUB. DATE
February 2005
SOURCE
Nature;2/17/2005, Vol. 433 Issue 7027, p674
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the sanctions faced by researchers involved in a gene-therapy trial leading to a teenagers death in 1999 in the U.S. Estimated amount agreed for the out-of-court settlement on the case; Terms of the agreement included in the settlement; Basis of the court's decision.
ACCESSION #
16113721

 

Related Articles

  • A tragic setback. Check, Erika // Nature;11/14/2002, Vol. 420 Issue 6912, p116 

    Reports that an unnamed child who received gene-therapy for severe combined immune deficiency has developed a leukemia-like condition thought to be the result of the treatment. Number of children who were cured by the treatment, administered in a French trial led by Alain Fischer and Marina...

  • Games, information, and evidence production: with application to English legal history. Sanchirico, Chris William // American Law & Economics Review;Fall2000, Vol. 2 Issue 2, p342 

    Examines the regulation of activities outside the courtroom. Trade-off in system design between the fixed costs of hearings and the cost of the evidence produced; Trends in the historical evolution of English civil process; Influence of the legal system on activities outside the courtroom.

  • Association Must Pay $1.2 Million for Discrimination.  // Community Association Management Insider;Aug2010, Vol. 10 Issue 1, p1 

    The article reports that three Jewish members of an association were sanctioned by the jury to pay 600,000 dollars for the violation of their civil rights and 150,000 dollars for nuissance as a settlement for the civil rights trial they filed against an association in Plymouth County, Massachusetts.

  • Cytokine profile assessment of mesothelioma patients treated with escalating doses of intrapleurally administered, genetically modified PA1STK cells and a twice daily regiment of ganciclovir. a Phase I clinical trial  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p229 

    An abstract of the article "Cytokine Profile Assessment of Mesothelioma Patients Treated with Escalating Doses of Intrapleurally Administered, Genetically Modified PA1STK Cells and a Twice Daily Regiment of Ganciclovir. A Phase I Clinical Trial," by Patrick S. Byrne and colleagues is presented.

  • RAC tries to regain foothold. Ready, Tinker // Nature Medicine;Sep2001, Vol. 7 Issue 9, p983 

    Reports that the U.S.-based National Institutes of Health's Recombinant Advisory Committee (RAC) is trying to regain control over reviewing of all gene therapy clinical trials in the nation, as of September 2001. Views of the researcher regarding the revival; Criticism of the public...

  • 'Shocked': Mass Torts and Aggregate Asbestos Litigation After Amchem and Ortiz. Issacharoff, Samuel // Texas Law Review;Jun2002, Vol. 80 Issue 7, p1925 

    Comments on an article about mass torts and aggregate asbestos litigation after the Supreme Court's rejection of the use of class-action settlement devices in Amchem Products Inc. versus Windsor and Ortiz versus Fibreboard Corp. cases. Consequence of a concentrated and developed market in...

  • Offer of Judgment Rules in Puerto Rico and Florida. Rojas, Ra�l // Revista de Derecho Puertorrique�o;2009, Vol. 49 Issue 1, p1 

    The article discusses the system of offer of judgment rules in Florida and Puerto Rico. It presents U.S. Bureau of Justice Statistics data including the number of cases per year from 1997 to 2006 and percentages of civil type cases. It explores civil procedure in Puerto Rico and Florida, court...

  • GENE THERAPY: TRIALS AND TRIBULATIONS. Somia, Nikunj; Verma, Inder M. // Nature Reviews Genetics;Nov2000, Vol. 1 Issue 2, p91 

    The art and science of gene therapy has received much attention of late. The tragic death of 18-year-old Jesse Gelsinger, a volunteer in a Phase I clinical trial, has overshadowed the successful treatment of three children suffering from a rare but fatal immunological disease. In the light of...

  • Gene therapy for HIV ready for human trials.  // Dermatology Times;Jan1997, Vol. 18 Issue 1, p73 

    Reports on the Food and Drug Administration's approval of SyStemix Inc.'s proposal to start human trials of its gene therapy for HIV infection.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics